Patent Grant
12121030
The present disclosure relates generally to glass compositions and articles incorporating such compositions.
Consumer electronics articles, including touch-activated or touch-interactive devices, such as screen surfaces (e.g., surfaces of electronic devices having user-interactive capabilities that are activated by touching specific portions of the surfaces), have become increasingly more prevalent. As the extent to which the touch screen-based interactions between a user and a device increases, so too does the likelihood of the surface harboring microorganisms (e.g., bacteria, fungi, viruses, and the like) that can be transferred from user to user. Moreover, the housings which incorporate the touch-activated or touch-interactive devices also include surfaces that harbor such microorganisms that can be transferred from user to user. The concern of microorganism transfer is also a concern with equipment, furniture and architectural articles used in medical or office settings and many other articles in which users come into contact with surfaces.
To minimize the presence of microbes on various materials, so-called “antimicrobial” properties have been imparted to a variety of glasses; however, there is a need to provide entire articles (including the housing and any glasses used as cover glass) that also exhibit antimicrobial properties. Accordingly, antimicrobial articles useful for certain applications should be durable enough for the purpose for which they are used, while also providing continuous antimicrobial properties that are passive or do not require additional activation by a user or outside source (e.g., UV light). In addition, antimicrobial glasses and articles should provide controlled antimicrobial activity.
A first aspect of the present disclosure pertains to an article that includes a carrier and a glass. Examples of suitable carriers include polymers, monomers, binders, solvents, and other materials used to form molded articles, formed articles, coatings on substrates or other such articles. Exemplary coatings may include anti-fricative coatings, coatings exhibiting a low coefficient of friction, or coatings that form a surface exhibiting a low coefficient of friction.
The glass of one or more embodiments may also include a composition that includes, in mole percent: SiO2 in the range from about 40 to about 70, Al2O3 in the range from about 0 to about 20, a copper-containing oxide in the range from about 10 to about 50, CaO in the range from about 0 to about 15, MgO in the range from about 0 to about 15, P2O5 in the range from about 0 to about 25, B2O3 in the range from about 0 to about 25, K2O in the range from about 0 to about 20, ZnO in the range from about 0 to about 5, Na2O in the range from about 0 to about 20, and Fe2O3 in the range from about 0 to about 5. In some embodiments, the amount of copper-containing oxide is greater than the amount of Al2O3 (which may be about 5 mole percent or less, in some cases). In some instances, the composition may be free of Al2O3. Examples of suitable copper-containing oxides can include CuO, Cu2O, or a combination thereof.
The article of one or more embodiments may include a plurality of Cu1+ ions, Cu metal or a combination thereof. In some instances, the glass may be substantially free of tenorite.
The glass of one or more embodiments may include a cuprite phase and a glass phase. In some embodiments, the cuprite phase may include crystals that have an average major dimension of about 5 micrometers (μm) or less, or even about 1 micrometer (μm) or less.
A second aspect of the present disclosure pertains to an article that includes a carrier and a glass with a plurality of Cu1+ ions, a degradable phase comprising at least one of B2O3, P2O5 and R2O, and a durable phase comprising SiO2. The glass may be formed from the compositions described herein. In some instances, the durable phase is present in an amount by weight that is greater than the degradable phase. The degradable phase of one or more embodiments leaches or is leachable in the presence of water.
The article may optionally include a cuprite phase, which may be dispersed in one or both of the degradable phase and the durable phase. The cuprite phase may have crystals having an average major dimension of about 5 micrometers (μm) or less, about 1 micrometer (μm) or less, or about 500 nanometers (nm) or less. The cuprite phase may comprise at least about 10 weight percent or at least about 20 weight percent of the glass.
In one or more embodiments, the glass includes a surface portion (having a depth of less than about 5 nanometers (nm)) that includes a plurality of copper ions. In some embodiments, at least 75% of the plurality of copper ions is Cu1+. In other embodiments, less than about 25% of the plurality of copper ions is Cu2+.
A third aspect of the present disclosure pertains to an article including a carrier; and an inorganic material, wherein the inorganic material comprises a surface and a plurality of Cu1+ ions disposed on the surface. The inorganic material may include a glass and may be formed form the compositions described herein. The inorganic material may be substantially free of tenorite.
In one or more embodiments, the plurality of Cu1+ ions may be dispersed in a glass network and/or a glass matrix. In some instances, the glass network includes atoms to which the plurality of Cu1+ ions is atomically bonded. The plurality of Cu1+ ions may include cuprite crystals that are dispersed in the glass matrix.
The carrier may include a polymer, a monomer, a binder, a solvent, or combinations thereof. Carriers may include anti-fricative materials such as for example, fluorocarbons, fluorinated silanes, and alkyl perfluorocarbon silanes. The polymer used in the embodiments described herein can include organic or inorganic polymers. Exemplary polymers may include a thermoplastic polymer, a polyolefin, a cured polymer, an ultraviolet- or UV-cured polymer, a polymer emulsion, a solvent-based polymer, and combinations thereof. Specific examples of monomers include catalyst curable monomers, thermally-curable monomers, radiation-curable monomers and combinations thereof. The articles described herein may include a glass to carrier ratio in the range from about 10:90 to about 90:10, based on weight percent.
The glasses and articles described herein may exhibit a 2 log reduction or greater in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under the EPA Test Method for Efficacy of Copper Alloy as a Sanitizer testing conditions (hereinafter, the “EPA Test”).
The glasses and articles described herein according to one or more embodiments may exhibit a 4 log reduction or greater (e.g., 5 log reduction or greater) in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under JIS Z 2801 (2000) testing conditions. One or more embodiments of the glasses and articles described herein also exhibit a 4 log reduction or greater (e.g., 5 log reduction or greater) in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa, Methicillin Resistant Staphylococcus aureus, and E. coli, under modified JIS Z 2801 (2000) testing conditions (hereinafter, “Modified JIS Z 2801 Test for Bacteria”). The Modified JIS Z 2801 (2000) Test for Bacteria is described in greater detail herein.
In one or more embodiments, the glasses and articles described herein according to one or more embodiments may exhibit a 2 log reduction or greater (e.g., 4 log reduction or greater, or a 5 log reduction or greater) in a concentration of Murine Norovirus, under modified JIS Z 2801 (2000) testing conditions for evaluating viruses (hereinafter, “Modified JIS Z 2801 for Viruses”). The Modified JIS Z 2801 (2000) Test for Viruses is described in greater detail herein.
In some embodiments, the glasses and articles may exhibit the log reductions described herein (i.e., under the EPA Test, the JIS Z 2801 testing conditions, the Modified JIS Z 2801 Test for Bacteria and/or the Modified JIS Z 2801 Test for Viruses), fora period of one month or greater or for a period of three months or greater. The one month period or three month period may commence at or after the formation of the glass, or at or after combination of the glass with a carrier.
In one or more embodiments, the articles leach the copper ions when exposed or in contact with a leachate. In one or more embodiments, the articles leach only copper ions when exposed to leachates including water.
The articles described herein may form the housing for an electronic device.
A fourth aspect of the present disclosure pertains to a method of making an antimicrobial article. In one or more embodiments, the method includes melting a glass composition to form a glass comprising a plurality of Cu1+ ions; and a glass phase, forming the glass into at least one of particulates and fibers, dispersing the at least one of particulates and fibers in a carrier, such as a polymer (as described herein), a monomer, or a binder, to provide a filled carrier and forming the filled carrier into the antimicrobial article. The glass composition may include the compositions described herein.
Additional features and advantages will be set forth in the detailed description which follows, and in part will be readily apparent to those skilled in the art from that description or recognized by practicing the embodiments as described herein, including the detailed description which follows, the claims, as well as the appended drawings.
It is to be understood that both the foregoing general description and the following detailed description are merely exemplary, and are intended to provide an overview or framework to understanding the nature and character of the claims. The accompanying drawings are included to provide a further understanding, and are incorporated in and constitute a part of this specification. The drawings illustrate one or more embodiment(s), and together with the description serve to explain principles and operation of the various embodiments.
Reference will now be made in detail to various embodiment(s), examples of which are illustrated in the accompanying drawings.
A first aspect of the present disclosure pertains to antimicrobial glass compositions and glasses made from or including such compositions. The antimicrobial properties of the glasses disclosed herein include antiviral and/or antibacterial properties. As used herein the term “antimicrobial,” means a material, or a surface of a material that will kill or inhibit the growth of bacteria, viruses and/or fungi. The term as used herein does not mean the material or the surface of the material will kill or inhibit the growth of all species microbes within such families, but that it will kill or inhibit the growth of one or more species of microbes from such families.
As used herein the term “log reduction” means— log (Ca/C0), where Ca=the colony form unit (CFU) number of the antimicrobial surface and C0=the colony form unit (CFU) of the control surface that is not an antimicrobial surface. As an example, a 3 log reduction equals about 99.9% of the bacteria, viruses and/or fungi killed and a Log Reduction of 5=99.999% of bacteria, viruses and/or fungi killed.
In one or more embodiments, the antimicrobial glasses include a Cu species. In one or more alternative embodiments, the Cu species may include Cu1+, Cu0, and/or Cu2+. The combined total of the Cu species may be about 10 wt % or more. However, as will be discussed in more detail below, the amount of Cu2+ is minimized or is reduced such that the antimicrobial glass is substantially free of Cu2+. The Cu1+ ions may be present on or in the surface and/or the bulk of the antimicrobial glass. In some embodiments, the Cu1+ ions are present in the glass network and/or the glass matrix of the antimicrobial glass. Where the Cu1+ ions are present in the glass network, the Cu1+ ions are atomically bonded to the atoms in the glass network. Where the Cu1+ ions are present in the glass matrix, the Cu1+ ions may be present in the form of Cu1+ crystals that are dispersed in the glass matrix. In some embodiments the Cu1+ crystals include cuprite (Cu2O). In such embodiments, where Cu1+ crystals are present, the material may be referred to as an antimicrobial glass ceramic, which is intended to refer to a specific type of glass with crystals that mayor may not be subjected to a traditional ceramming process by which one or more crystalline phases are introduced and/or generated in the glass. Where the Cu1+ ions are present in a non-crystalline form, the material may be referred to as an antimicrobial glass. In some embodiments, both Cu Cu1+ crystals and Cu1+ ions not associated with a crystal are present in the antimicrobial glasses described herein.
In one or more embodiments, the antimicrobial glass may be formed from a composition that can include, in mole percent, SiO2 in the range from about 40 to about 70, Al2O3 in the range from about 0 to about 20, a copper-containing oxide in the range from about 10 to about 30, CaO in the range from about 0 to about 15, MgO in the range from about 0 to about 15, P2O5 in the range from about 0 to about 25, B2O3 in the range from about 0 to about 25, K2O in the range from about 0 to about 20, ZnO in the range from about 0 to about 5, Na2O in the range from about 0 to about 20, and/or Fe2O3 in the range from about 0 to about 5. In such embodiments, the amount of the copper-containing oxide is greater than the amount of Al2O3. In some embodiments, the composition may include a content of R2O, where R may include K, Na, Li, Rb, Cs and combinations thereof.
In the embodiments of the compositions described herein, SiO2 serves as the primary glass-forming oxide. The amount of SiO2 present in a composition should be enough to provide glasses that exhibit the requisite chemical durability suitable for its use or application (e.g., touch applications, article housing etc.). The upper limit of SiO2 may be selected to control the melting temperature of the compositions described herein. For example, excess SiO2 could drive the melting temperature at 200 poise to high temperature sat which defects such as fining bubbles may appear or be generated during processing and in the resulting glass. Furthermore, compared to most oxides, SiO2 decreases the compressive stress created by an ion exchange process of the resulting glass. In other words, glass formed from compositions with excess SiO2 may not be ion-exchangeable to the same degree as glass formed from compositions without excess SiO2. Additionally or alternatively, SiO2 present in the compositions according to one or more embodiments could increase the plastic deformation prior break properties of the resulting glass. An increased SiO2 content in the glass formed from the compositions described herein may also increase the indentation fracture threshold of the glass.
In one or more embodiments, the composition includes SiO2 in an amount, in mole percent, in the range from about 40 to about 70, from about 40 to about 69, from about 40 to about 68, from about 40 to about 67, from about 40 to about 66, from about 40 to about 65, from about 40 to about 64, from about 40 to about 63, from about 40 to about 62, from about 40 to about 61, from about 40 to about 60, from about 41 to about 70, from about 42 to about 70, from about 43 to about 70, from about 44 to about 70, from about 45 to about 70, from about 46 to about 70, from about 47 to about 70, from about 48 to about 70, from about 49 to about 70, from about 50 to about 70, from about 41 to about 69, from about 42 to about 68, from about 43 to about 67, from about 44 to about 66, from about 45 to about 65, from about 46 to about 64, from about 47 to about 63, from about 48 to about 62, from about 49 to about 61, from about 50 to about 60 and all ranges and sub-ranges therebetween.
In one or more embodiments, the composition includes Al2O3 an amount, in mole percent, in the range from about 0 to about 20, from about 0 to about 19, from about 0 to about 18, from about 0 to about 17, from about 0 to about 16, from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11 from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about Oto about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1, from about 0.4 to about 1, from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3, from about 0 to about 0.2, from about 0 to about 0.1 and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of Al2O3. As used herein, the phrase “substantially free” with respect to the components of the composition and/or resulting glass means that the component is not actively or intentionally added to the compositions during initial batching or subsequent post processing (e.g., ion exchange process), but may be present as an impurity. For example, a composition, a glass may be described as being substantially free of a component, when the component is present in an amount of less than about 0.01 mol %.
The amount of Al2O3 may be adjusted to serve as a glass-forming oxide and/or to control the viscosity of molten compositions. Without being bound by theory, it is believed that when the concentration of alkali oxide (R2O) in a composition is equal to or greater than the concentration of Al2O3, the aluminum ions are found in tetrahedral coordination with the alkali ions acting as charge-balancers. This tetrahedral coordination greatly enhances various post-processing (e.g., ion exchange process) of glasses formed from such compositions. Divalent cation oxides (RO) can also charge balance tetrahedral aluminum to various extents. While elements such as calcium, zinc, strontium, and barium behave equivalently to two alkali ions, the high field strength of magnesium ions causes them to not fully charge balance aluminum in tetrahedral coordination, resulting in the formation of five- and six-fold coordinated aluminum. Generally, Al2O3 can play an important role in ion-exchangeable compositions and strengthened glasses since it enables a strong network backbone (i.e., high strain point) while allowing for the relatively fast diffusivity of alkali ions. However, when the concentration of Al2O3 is too high, the composition may exhibit lower liquidus viscosity and, thus, Al2O3 concentration may be controlled within a reasonable range. Moreover, as will be discussed in more detail below, excess Al2O3 has been found to promote the formation of Cu2+ ions, instead of the desired Cu1+ ions.
In one or more embodiments, the composition includes a copper-containing oxide in an amount, in mole percent, in the range from about 10 to about 50, from about 10 to about 49, from about 10 to about 48, from about 10 to about 47, from about 10 to about 46, from about 10 to about 45, from about 10 to about 44, from about 10 to about 43, from about 10 to about 42, from about 10 to about 41, from about 10 to about 40, from about 10 to about 39, from about 10 to about 38, from about 10 to about 37, from about 10 to about 36, from about 10 to about 35, from about 10 to about 34, from about 10 to about 33, from about 10 to about 32, from about 10 to about 31, from about 10 to about 30, from about 10 to about 29, from about 10 to about 28, from about 10 to about 27, from about 10 to about 26, from about 10 to about 25, from about 10 to about 24, from about 10 to about 23, from about 10 to about 22, from about 10 to about 21, from about 10 to about 20, from about 11 to about 50, from about 12 to about 50, from about 13 to about 50, from about 14 to about 50, from about 15 to about 50, from about 16 to about 50, from about 17 to about 50, from about 18 to about 50, from about 19 to about 50, from about 20 to about 50, from about 10 to about 30, from about 11 to about 29, from about 12 to about 28, from about 13 to about 27, from about 14 to about 26, from about 15 to about 25, from about 16 to about 24, from about 17 to about 23, from about 18 to about 22, from about 19 to about 21 and all ranges and sub-ranges therebetween. In one or more specific embodiments, the copper-containing oxide may be present in the composition in an amount of about 20 mole percent, about 25 mole percent, about 30 mole percent or about 35 mole percent. The copper-containing oxide may include CuO, Cu2O and/or combinations thereof.
The copper-containing oxides in the composition form the Cu1+ ions present in the resulting glass. Copper may be present in the composition and/or the glasses including the composition in various forms including Cu0, Cu1+, and Cu2+. Copper in the Cu0 or Cu1+ forms provide antimicrobial activity. However forming and maintaining these states of antimicrobial copper are difficult and often, in known compositions, Cu2+ ions are formed instead of the desired Cu0 or Cu1+ ions.
In one or more embodiments, the amount of copper-containing oxide is greater than the amount of Al2O3 in the composition. Without being bound by theory it is believed that an about equal amount of copper-containing oxides and Al2O3 in the composition results in the formation of tenorite (CuO) instead of cuprite (Cu2O). The presence of tenorite decreases the amount of Cu1+ in favor of Cu2+ and thus leads to reduced antimicrobial activity. Moreover, when the amount of copper-containing oxides is about equal to the amount of Al2O3, aluminum prefers to be in a four-fold coordination and the copper in the composition and resulting glass remains in the Cu2+ form so that the charge remains balanced. Where the amount of copper-containing oxide exceeds the amount of Al2O3, then it is believed that at least a portion of the copper is free to remain in the Cu1+ state, instead of the Cu2+ state, and thus the presence of Cu1+ ions increases.
The composition of one or more embodiments includes P2O5 in an amount, in mole percent, in the range from about 0 to about 25, from about 0 to about 22, from about 0 to about 20, from about 0 to about 18, from about 0 to about 16, from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about Oto about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1, from about 0.4 to about 1, from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about Oto about 0.1 and all ranges and sub-ranges therebetween. In some embodiments, the composition includes about 10 mole percent or about 5 mole percent P2O5 or, alternatively, may be substantially free of P2O5.
In one or more embodiments, P2O5 forms at least part of a less durable phase or a degradable phase in the glass. The relationship between the degradable phase(s) of the glass and antimicrobial activity is discussed in greater detail herein. In one or more embodiments, the amount of P2O5 may be adjusted to control crystallization of the composition and/or glass during forming. For example, when the amount of P2O5 is limited to about 5 mol % or less or even 10 mol % or less, crystallization may be minimized or controlled to be uniform. However, in some embodiments, the amount or uniformity of crystallization of the composition and/or glass may not be of concern and thus, the amount of P2O5 utilized in the composition may be greater than 10 mol %.
In one or more embodiments, the amount of P2O5 in the composition may be adjusted based on the desired damage resistance of the glass, despite the tendency for P2O5 to form a less durable phase or a degradable phase in the glass. Without being bound by theory, P2O5 can decrease the melting viscosity relative to SiO2. In some instances, P2O5 is believed to help to suppress zircon breakdown viscosity (i.e., the viscosity at which zircon breaks down to form ZrO2) and may be more effective in this regard than SiO2. When glass is to be chemically strengthened via an ion exchange process, P2O5 can improve the diffusivity and decrease ion exchange times, when compared to other components that are sometimes characterized as network formers (e.g., SiO2 and/or B2O3).
The composition of one or more embodiments includes B2O3 in an amount, in mole percent, in the range from about Oto about 25, from about Oto about 22, from about 0 to about 20, from about 0 to about 18, from about 0 to about 16, from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1, from about 0.4 to about 1, from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3, from about 0 to about 0.2, from about 0 to about 0.1 and all ranges and sub-ranges therebetween. In some embodiments, the composition includes a non-zero amount of B2O3, which may be, for example, about 10 mole percent or about 5 mole percent. The composition of some embodiments may be substantially free of B2O3.
In one or more embodiments, B2O3 forms a less durable phase or a degradable phase in the glass formed form the composition. The relationship between the degradable phase(s) of the glass and antimicrobial activity is discussed in greater detail herein. Without being bound by theory, it is believed the inclusion of B2O3 in compositions imparts damage resistance in glasses incorporating such compositions, despite the tendency for B2O3 to form a less durable phase or a degradable phase in the glass. The composition of one or more embodiments includes one or more alkali oxides (R2O) (e.g., Li2O, Na2O, K2O, Rb2O and/or Cs2O). In some embodiments, the alkali oxides modify the melting temperature and/or liquidus temperatures of such compositions. In one or more embodiments, the amount of alkali oxides may be adjusted to provide a composition exhibiting a low melting temperature and/or a low liquidus temperature. Without being bound by theory, the addition of alkali oxide(s) may increase the coefficient of thermal expansion (CTE) and/or lower the chemical durability of the antimicrobial glasses that include such compositions. In some cases these attributes may be altered dramatically by the addition of alkali oxide(s).
In some embodiments, the antimicrobial glasses disclosed herein may be chemically strengthened via an ion exchange process in which the presence of a small amount of alkali oxide (such as Li2O and Na2O) is required to facilitate ion exchange with larger alkali ions (e.g., K+), for example exchanging smaller alkali ions from an antimicrobial glass with larger alkali ions from a molten salt bath containing such larger alkali ions. Three types of ion exchange can generally be carried out. One such ion exchange includes a Na+-for-Li+ exchange, which results in a deep depth of layer but low compressive stress. Another such ion exchange includes a K+-for-Li+ exchange, which results in a small depth of layer buta relatively large compressive stress. A third such ion exchange includes a K+-for-Na+ exchange, which results in intermediate depth of layer and compressive stress. A sufficiently high concentration of the small alkali oxide in compositions may be necessary to produce a large compressive stress in the antimicrobial glass including such compositions, since compressive stress is proportional to the number of alkali ions that are exchanged out of the antimicrobial glass.
In one or more embodiments, the composition includes K2O in an amount in the range from about 0 to about 20, from about 0 to about 18, from about 0 to about 16, from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1 from about 0.4 to about 1 from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1 and all ranges and sub-ranges therebetween. In some embodiments, the composition includes a non-zero amount of K2O or, alternatively, the composition may be substantially free, as defined herein, of K2O. In addition to facilitating ion exchange, where applicable, in one or more embodiments, K2O can also form a less durable phase or a degradable phase in the glass formed form the composition. The relationship between the degradable phase(s) of the glass and antimicrobial activity is discussed in greater detail herein.
In one or more embodiments, the composition includes Na2O in an amount in the range from about 0 to about 20, from about 0 to about 18, from about 0 to about 16, from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1, from about 0.4 to about 1, from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1 and all ranges and sub-ranges therebetween. In some embodiments, the composition includes a non-zero amount of Na2O or, alternatively, the composition may be substantially free, as defined herein, of Na2O.
In one or more embodiments, the composition may include one or more divalent cation oxides, such as alkaline earth oxides and/or ZnO. Such divalent cation oxides may be included to improve the melting behavior of the compositions. With respect to ion exchange performance, the presence of divalent cations can act to decrease alkali mobility and thus, when larger divalent cation oxides are utilized, there may be a negative effect on ion exchange performance. Furthermore, smaller divalent cation oxides generally help the compressive stress developed in an ion-exchanged glass more than the larger divalent cation oxides. Hence, divalent cation oxides such as MgO and ZnO can offer advantages with respect to improved stress relaxation, while minimizing the adverse effects on alkali diffusivity.
In one or more embodiments, the composition includes CaO in an amount, in mole percent, in the range from about 0 to about 15, from about 0 to about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1, from about 0.4 to about 1, from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1 and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of CaO.
In one or more embodiments, the composition includes MgO in an amount, m mole percent, in the range from about Oto about 15, from about Oto about 14, from about 0 to about 13, from about 0 to about 12, from about 0 to about 11, from about 0 to about 10, from about 0 to about 9, from about 0 to about 8, from about 0 to about 7, from about 0 to about 6, from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1, from about 0.4 to about 1, from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3, from about 0 to about 0.2, from about 0 to about 0.1 and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of MgO.
The composition of one or more embodiments may include ZnO in an amount, in mole percent, in the range from about 0 to about 5, from about 0 to about 4, from about 0 to about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1, from about 0.4 to about 1, from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3 from about 0 to about 0.2, from about 0 to about 0.1 and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of ZnO.
The composition of one or more embodiments may include Fe2O3, in mole percent, in the range from about Oto about 5, from about Oto about 4, from about Oto about 3, from about 0 to about 2, from about 0 to about 1, from about 0.1 to about 1, from about 0.2 to about 1, from about 0.3 to about 1, from about 0.4 to about 1, from about 0.5 to about 1, from about 0 to about 0.5, from about 0 to about 0.4, from about 0 to about 0.3, from about 0 to about 0.2, from about 0 to about 0.1 and all ranges and sub-ranges therebetween. In some embodiments, the composition is substantially free of Fe2O3.
In one or more embodiments, the composition may include one or more colorants. Examples of such colorants include NiO, TiO2, Fe2O3, Cr2O3, Co3O4 and other known colorants. In some embodiments, the one or more colorants may be present in an amount in the range up to about 10 mol %. In some instances, the one or more colorants may be present in an amount in the range from about 0.01 mol % to about 10 mol %, from about 1 mol % to about 10 mol %, from about 2 mol % to about 10 mol %, from about 5 mol % to about 10 mol %, from about 0.01 mol % to about 8 mol %, or from about 0.01 mol % to about 5 mol %.
In one or more embodiments, the composition may include one or more nucleating agents. Exemplary nucleating agents include TiO2, ZrO2 and other known nucleating agents in the art. The composition can include one or more different nucleating agents. The nucleating agent content of the composition may be in the range from about 0.01 mol % to about 1 mol %. In some instances, the nucleating agent content may be in the range from about 0.01 mol % to about 0.9 mol %, from about 0.01 mol % to about 0.8 mol %, from about 0.01 mol % to about 0.7 mol %, from about 0.01 mol % to about 0.6 mol %, from about 0.01 mol % to about 0.5 mol %, from about 0.05 mol % to about 1 mol %, from about 0.1 mol % to about 1 mol %, from about 0.2 mol % to about 1 mol %, from about 0.3 mol % to about 1 mol %, or from about 0.4 mol % to about 1 mol %, and all ranges and sub-ranges therebetween.
The glasses formed from the compositions may include a plurality of Cu1+ ions. In some embodiments, such Cu1+ ions form part of the glass network and may be characterized as a glass modifier. Without being bound by theory, where Cu1+ ions are part of the glass network, it is believed that during typical glass formation processes, the cooling step of the molten glass occurs too rapidly to allow crystallization of the copper-containing oxide (e.g., CuO and/or Cu2O). Thus the Cu1+ remains in an amorphous state and becomes part of the glass network. In some cases, the total amount of Cu1+ ions, whether they are in a crystalline phase or in the glass matrix, may be even higher, such as up to 40 mol %, up to 50 mol %, or up to 60 mol %.
In one or more embodiments, the glasses formed form the compositions disclosed herein include Cu1+ ions that are dispersed in the glass matrix as Cu1+ crystals. In one or more embodiments, the Cu1+ crystals may be present in the form of cuprite. The cuprite present in the glass may form a phase that is distinct from the glass matrix or glass phase. In other embodiments, the cuprite may form part of or may be associated with one or more glasses phases (e.g., the durable phase described herein). The Cu1+ crystals may have an average major dimension of about 5 micrometers (μm) or less, 4 micrometers (μm) or less, 3 micrometers (μm) or less, 2 micrometers (μm) or less, about 1.9 micrometers (μm) or less, about 1.8 micrometers (μm) or less, about 1.7 micrometers (μm) or less, about 1.6 micrometers (μm) or less, about 1.5 micrometers (μm) or less, about 1.4 micrometers (μm) or less, about 1.3 micrometers (μm) or less, about 1.2 micrometers (μm) or less, about 1.1 micrometers or less, 1 micrometers or less, about 0.9 micrometers (μm) or less, about 0.8 micrometers (μm) or less, about 0.7 micrometers (μm) or less, about 0.6 micrometers (μm) or less, about 0.5 micrometers (μm) or less, about 0.4 micrometers (μm) or less, about 0.3 micrometers (μm) or less, about 0.2 micrometers (μm) or less, about 0.1 micrometers (μm) or less, about 0.05 micrometers (μm) or less, and all ranges and sub-ranges therebetween. As used herein and with respect to the phrase “average major dimension”, the word “average” refers to a mean value and the word “major dimension” is the greatest dimension of the particle as measured by SEM. In some embodiments, the cuprite phase may be present in the antimicrobial glass in an amount of at least about 10 wt %, at least about 15 wt %, at least about 20 wt %, at least about 25 wt % and all ranges and subranges therebetween of the antimicrobial glass.
In some embodiments, the glasses may include about 70 wt % Cu1+ or more and about 30 wt % of Cu2+ or less. The Cu2+ ions may be present in tenorite form and/or even in the glass (i.e., not as a crystalline phase).
In some embodiments, the total amount of Cu by wt % in the glasses may be in the range from about 10 to about 30, from about 15 to about 25, from about 11 to about 30, from about 12 to about 30, from about 13 to about 30, from about 14 to about 30, from about 15 to about 30, from about 16 to about 30, from about 17 to about 30, from about 18 to about 30, from about 19 to about 30, from about 20 to about 30, from about 10 to about 29, from about 10 to about 28, from about 10 to about 27, from about 10 to about 26, from about 10 to about 25, from about 10 to about 24, from about 10 to about 23, from about 10 to about 22, from about 10 to about 21, from about 10 to about 20, from about 16 to about 24, from about 17 to about 23, from about 18 to about 22, from about 19 to about 21 and all ranges and sub-ranges therebetween. In one or more embodiments, the ratio of Cu1+ ions to the total amount Cu in the glass is about 0.5 or greater, 0.55 or greater, 0.6 or greater, 0.65 or greater, 0.7 or greater, 0.75 or greater, 0.8 or greater, 0.85 or greater, 0.9 or greater or even 1 or greater, and all ranges and sub-ranges therebetween. The amount of Cu and the ratio of Cu1+ ions to total Cu may be determined by inductively coupled plasma (ICP) techniques known in the art.
In some embodiments, the glass may exhibit a greater amount of Cu1+ and/or Cu0 than Cu2+. For example, based on the total amount of Cu1+, Cu2+ and Cu0 in the glasses, the percentage of Cu1+ and Cu0 combined, may be in the range from about 50% to about 99.9%, from about 50% to about 99%, from about 50% to about 95%, from about 50% to about 90%, from about 55% to about 99.9%, from about 60% to about 99.9%, from about 65% to about 99.9%, from about 70% to about 99.9%, from about 75% to about 99.9%, from about 80% to about 99.9%, from about 85% to about 99.9%, from about 90% to about 99.9%, from about 95% to about 99.9%, and all ranges and sub-ranges there between. The relative amounts of Cu1+, Cu2+ and Cu0 may be determined using x-ray photoluminescence spectroscopy (XPS) techniques known in the art. The tables below report these amounts as measured by XPS. Specifically, the tables report the amount of Cu2+ and the combination of Cu1+ and Cu0. Without being bound by theory, it is believed that most of the embodiments shown in Table 1 show copper as being present in the form of Cu1+, under the conditions the XPS was performed.
The antimicrobial glass comprise sat least a first phase and second phase. In one or more embodiments, the antimicrobial glass may include two or more phases wherein the phases differ based on the ability of the atomic bonds in the given phase to withstand interaction with a leachate. Specifically, the glass of one or more embodiments may include a first phase that may be described as a degradable phase and a second phase that may be described as a durable phase. The phrases “first phase” and “degradable phase” may be used interchangeably. The phrases “second phase” and “durable phase” may be used interchangeably. As used herein, the term “durable” refers to the tendency of the atomic bonds of the durable phase to remain intact during and after interaction with a leachate. As used herein, the term “degradable” refers to the tendency of the atomic bonds of the degradable phase to break during and after interaction with one or more leachates. In one or more embodiments, the durable phase includes SiO2 and the degradable phase includes at least one of B2O3, P2O5 and R2O (where R can include any one or more of K, Na, Li, Rb, and Cs). Without being bound by theory, it is believed that the components of the degradable phase (i.e., B2O3, P2O5 and/or R2O) more readily interact with a leachate and the bonds between these components to one another and to other components in the antimicrobial glass more readily break during and after the interaction with the leachate. Leachates may include water, acids or other similar materials. In one or more embodiments, the degradable phase withstands degradation for 1 week or longer, 1 month or longer, 3 months or longer, or even 6 months or longer. In some embodiments, longevity may be characterized as maintaining antimicrobial efficacy over a specific period of time.
In one or more embodiments, the durable phase is present in an amount by weight that is greater than the amount of the degradable phase. In some instances, the degradable phase forms islands and the durable phase forms the sea surrounding the islands (i.e., the durable phase). In one or more embodiments, either one or both of the durable phase and the degradable phase may include cuprite. The cuprite in such embodiments may be dispersed in the respective phase or in both phases.
In some embodiments, phase separation occurs without any additional heat treatment of the antimicrobial glass. In some embodiments, phase separation may occur during melting and may be present when the glass composition is melted at temperatures up to and including about 1600° C. or 1650° C. When the glass is cooled, the phase separation is maintained.
The antimicrobial glass may be provided as a sheet or may have another shape such as particulate, fibrous, and the like. In one or more embodiments, as shown in
The antimicrobial glass of one or more embodiments may a 2 log reduction or greater (e.g., 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5 and all ranges and sub-ranges therebetween) in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa, Methicillin Resistant Staphylococcus aureus, and E. coli, under the EPA Test. In some instances, the antimicrobial glass exhibits at least a 4 log reduction, a 5 log reduction or even a 6 log reduction in the concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli under the EPA Test.
The glasses described herein according to one or more embodiments may exhibit a 4 log reduction or greater (e.g., 5 log reduction or greater) in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under JIS Z 2801 (2000) testing conditions. One or more embodiments of the glasses described herein also exhibit a 4 log reduction or greater (e.g., 5 log reduction or greater) in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa, Methicillin Resistant Staphylococcus aureus, and E. coli, under the Modified JIS Z 2801 Test for Bacterial. As used herein, Modified JIS Z 2801 Test for Bacteria includes evaluating the bacteria under the standard JIS Z 2801 (2000) test with modified conditions comprising heating the glass or article to a temperature of about 23 degrees Celsius to about 37 degrees Celsius at a humidity of about 38 percent to about 42 percent for about 6 hours.
In one or more embodiments described herein, the antimicrobial glasses exhibit a 2 log reduction or greater, a 3 log reduction or greater, a 4 log reduction or greater, or a 5 log reduction or greater in Murine Norovirus under a Modified JIS Z 2801 for Viruses test. The Modified JIS Z 2801 (2000) Test for Viruses includes the following procedure. For each material (e.g., the articles or glass of one or more embodiments, control materials, and any comparative glasses or articles) to be tested, three samples of the material (contained in individual sterile petri dishes) are each inoculated with a 20 μL aliquot of a test virus (where antimicrobial activity is measured) or a test medium including an organic soil load of 5% fetal bovine serum with or without the test virus (where cytotoxicity is measured). The inoculum is then covered with a film and the film is pressed down so the test virus and/or test medium spreads over the film, but does not spread past the edge of the film. The exposure time begins when each sample was inoculated. The inoculated samples are transferred to a control chamber set to room temperature (about 20° C.) in a relative humidity of 42% for 2 hours. Exposure time with respect to control samples are discussed below. Following the 2-hour exposure time, the film is lifted off using sterile forceps and a 2.00 mL aliquot of the test virus and/or test medium is pipetted individually onto each sample of material and the underside of the film (or the side of the film exposed to the sample) used to cover each sample. The surface of each sample is individually scraped with a sterile plastic cell scraper to collect the test virus or test medium. The test virus and/or test medium is collected (at 10−2 dilution), mixed using a vortex type mixer and serial 10-fold dilutions are prepared. The dilutions are then assayed for antimicrobial activity and/or cytotoxicity.
To prepare a control sample for testing antimicrobial activity (which are also referred to as “zero-time virus controls”) for the Modified JIS Z 2801 Test for Viruses, three control samples (contained in individual sterile petri dishes) are each inoculated with a 20 μL aliquot of the test virus. Immediately following inoculation, a 2.00 mL aliquot of test virus is pipetted onto each control sample. The surface of each sample was individually scraped with a sterile plastic cell scraper to collect test virus. The test virus is collected (at 10−2 dilution), mixed using a vortex type mixer, and serial 10-fold dilutions were prepared. The dilutions are assayed for antimicrobial activity.
To prepare controls samples for cytotoxicity (which are also referred to as “2 hour control virus”) for the Modified JIS Z 2801 Test for Viruses, one control sample (contained in an individual sterile petri dish) is inoculated with a 20 μL aliquot of a test medium containing an organic soil load (5% fetal bovine serum), without the test virus. The inoculum is covered with a film and the film is pressed so the test medium spreads over the film but does not spread past the edge of the film. The exposure time begins when each control sample is inoculated. The control sample is transferred to a controlled chamber set to room temperature (20° C.) in a relative humidity of 42% for a duration of 2 hours exposure time. Following this exposure time, the film is lifted off using sterile forceps and a 2.00 mL aliquot of the test medium is pipetted individually onto each control sample and the underside of the film (the side exposed to the sample). The surface of each sample is individually scraped with a sterile plastic cell scraper to collect the test medium. The test medium is collected (at 10−2 dilution), mixed using a vortex type mixer, and serial 10-fold dilutions were prepared. The dilutions were assayed for cytotoxicity.
The antimicrobial glass of one or more embodiments may exhibit the log reduction described herein for long periods of time. In other words, the antimicrobial glass may exhibit extended or prolonged antimicrobial efficacy. For example, in some embodiments, the antimicrobial glass may exhibit the log reductions described herein under the EPA Test, the JIS Z 2801 (2000) testing conditions, the Modified IS Z 2801 Test for Bacteria and/or the Modified JIS Z 2801 Test for Viruses for up to 1 month, up to 3 months, up to 6 months, or up to 12 months after the antimicrobial glass is formed or after the antimicrobial glass is combined with a carrier (e.g., polymers, monomers, binders, solvents and the like). These time periods may start at or after the antimicrobial glass is formed or combined with a carrier.
One or more embodiments, the antimicrobial glass may exhibit a preservative function, when combined with carriers described herein. In such embodiments, the antimicrobial glass may kill or eliminate, or reduce the growth of various foulants in the carrier. Foulants include fungi, bacteria, viruses and combinations thereof.
In one or more embodiments, the glasses and/or articles described herein leach the copper ions when exposed or in contact with a leachate. In one or more embodiments, the glass leaches only copper ions when exposed to leachates including water.
In one or more embodiments, the antimicrobial glass and/or articles described herein may have a tunable antimicrobial activity release. The antimicrobial activity of the glass and/or articles may be caused by contact between the antimicrobial glass and a leachate, such as water, where the leachate causes Cu1+ ions to be released from the antimicrobial glass. This action may be described as water solubility and the water solubility can be tuned to control the release of the Cu1+ ions.
In some embodiments, where the Cu1+ ions are disposed in the glass network and/or form atomic bonds with the atoms in the glass network, water or humidity breaks those bonds and the Cu1+ ions available for release and may be exposed on the glass or glass ceramic surface.
In one or more embodiments, the antimicrobial glass may be formed using formed in low cost melting tanks that are typically used for melting glass compositions such as soda lime silicate. The antimicrobial glass may be formed into a sheet using forming processes known in the art. For instance, example forming methods include float glass processes and down-draw processes such as fusion draw and slot draw.
The antimicrobial glass may be incorporated into a variety of articles, either alone or in combination with other materials, such as electronic devices (e.g., mobile phones, smart phones, tablets, video players, information terminal devices, laptop computer, etc.), architectural structures (e.g., countertops or walls), appliances (e.g., cooktops, refrigerator and dishwasher doors, etc.), information displays (e.g., whiteboards), and automotive components (e.g., dashboard panels, windshields, window components, etc.). When used in such articles, the antimicrobial glass can form at least part of the housing and/or display.
After formation, the antimicrobial glass may be formed into sheets and may be shaped, polished or otherwise processed for a desired end use. In some instances, the antimicrobial glass may be ground to a powder or particulate form. In other embodiments, the particulate antimicrobial glass may be combined with other materials or carriers into articles for various end uses. The combination of the antimicrobial glass and such other materials or carriers may be suitable for injection molding, extrusion or coatings or may be drawn into fibers. Such other materials or carriers may include polymers, monomers, binders, solvents, or a combination thereof as described herein. The polymer used in the embodiments described herein can include a thermoplastic polymer, a polyolefin, a cured polymer, an ultraviolet- or UV-cured polymer, a polymer emulsion, a solvent-based polymer, and combinations thereof. Examples of suitable polymers include, without limitation: thermoplastics including polystyrene (PS), high impact PS, polycarbonate (PC), nylon (sometimes referred to as polyamide (PA)), poly(acrylonitrile-butadiene-styrene) (ABS), PC-ABS blends, polybutyleneterephthalate (PBT) and PBT co-polymers, polyethyleneterephthalate (PET) and PET co-polymers, polyolefins (PO) including polyethylenes (PE), polypropylenes (PP), cyclicpolyolefins (cyclic-PO), modified polyphenylene oxide (mPPO), polyvinylchloride (PVC), acrylic polymers including polymethyl methacrylate (PMMA), thermoplastic elastomers (TPE), thermoplastic urethanes (TPU), polyetherimide (PEI) and blends of these polymers with each other. Suitable injection moldable thermosetting polymers include epoxy, acrylic, styrenic, phenolic, melamine, urethanes, polyesters and silicone resins. In other embodiments, the polymers may be dissolved in a solvent or dispersed as a separate phase in a solvent and form a polymer emulsion, such as a latex (which is a water emulsion of a synthetic or natural rubber, or plastic obtained by polymerization and used especially in coatings (as paint) and adhesives). Polymers may include fluorinated silanes or other low friction or anti-fricative materials. The polymers can contain impact modifiers, flame retardants, UV inhibitors, antistatic agents, mold release agents, fillers including glass, metal or carbon fibers or particles (including spheres), talc, clay or mica and colorants. Specific examples of monomers include catalyst curable monomers, thermally-curable monomers, radiation-curable monomers and combinations thereof.
In one example, acrylic latex paint may be combined with 20 wt % antimicrobial glass in particulate form and having a diameter of about 5 micrometers (μm). In some embodiments, the resulting combination of paint and antimicrobial glass included about 4 wt % CuO. In one or more embodiments, when combined with a carrier such as a polymer, monomer, binder or solvent, the amount of antimicrobial glass may be in the range from about 50 wt % to about 85 wt %. In some embodiments, the antimicrobial glass may be present in an amount in the range from about 55 wt % to about 85 wt %, from about 60 wt % to about 85 wt %, from about 65 wt % to about 85 wt %, from about 50 wt % to about 80 wt %, from about 50 wt % to about 75 wt %, from about 50 wt % to about 70 wt % and all ranges and sub-ranges therebetween, based on the total weight of the antimicrobial glass and carrier. In such embodiments, the total amount of CuO present in the may be about 20 wt %. In other embodiments, the amount of Cu2O present in the antimicrobial glass and carrier combination may be in the range from about 10 wt % to about 20 wt % or more specifically, about 15%. The ratio of antimicrobial glass to carrier, by vol %, may be in the range from about 90:10 to about 10:90, or more specifically about 50:50.
In one or more embodiments, the antimicrobial glass may be provided in particulate form and may have a diameter in the range from about 0.1 micrometers (μm) to about 10 micrometers (μm), from about 0.1 micrometers (μm) to about 9 micrometers (μm), from about 0.1 micrometers (μm) to about 8 micrometers (μm), from about 0.1 micrometers (μm) to about 7 micrometers (μm), from about 0.1 micrometers (μm) to about 6 micrometers (μm), from about 0.5 micrometers (μm) to about 10 micrometers (μm), from about 0.75 micrometers (μm) to about 10 micrometers (μm), from about 1 micrometers (μm) to about 10 micrometers (μm), from about 2 micrometers (μm) to about 10 micrometers (μm), from about 3 micrometers (μm) to about 10 micrometers (μm), from about 3 micrometers (μm) to about 6 micrometers (μm), from about 3.5 micrometers (μm) to about 5.5 micrometers (μm), from about 4 micrometers (μm) to about 5 micrometers (μm), and all ranges and sub-ranges therebetween. The particulate antimicrobial glass may be substantially spherical or may have an irregular shape. The particles may be provided in a solvent and thereafter dispersed in a carrier as otherwise described herein.
Without being bound by theory it is believed that the combination of the antimicrobial glass described herein and a carrier, such as latex paint, provides substantially greater antimicrobial efficacy as compared to the same latex paint that includes only Cu2O (cuprite), even when the same amount of copper is utilized. The presence of Cu1+ crystals in the antimicrobial glasses described herein, even when present as cuprite, tends to remain in the Cu1+ state. Without being bound by theory, it is believed that when Cu2O is provided alone, separate from the glasses described herein, the Cu ions are less stable and may change to Cu2+ from Cu1+.
The antimicrobial performance of the articles described herein may be impacted by the presence of a thin layer of polymer on the surface of the article. This thin layer may exhibit hydrophobic properties and may block the active copper species (Cu1+) from exposure to air or from leaching to the surface. In one or more embodiments, the articles may use polymers that have balanced hydrophobic-hydrophilic properties that facilitate leaching of the active copper species. Examples of such polymers include hygroscopic/water soluble polymers and surfactants, amphiphilic polymers and/or a combination of amphiphilic polymers and hygroscopic materials. In one or more embodiments, the exposure to air and/or leaching of the active copper species to the surface may be facilitated by providing articles with an exposed treated surface. In one or more embodiments, the exposed treated surface is a surface that has been mechanically or chemically treated to expose at least some of the glass contained in the article to the air or to provide some of the glass at the surface of the article. Specific methods for providing an exposed treated surface include sanding, polishing, plasma treating (e.g., air, N2, O2, H2, N2 and/or Argon based plasma) and other methods that will remove a thin layer of the polymer material. In one or more alternative embodiments, the exposed treated surface includes functional groups, particularly hydroxyl and carbonyl groups, which are introduced into or to the exposed treated surface, to make such surface more hydrophilic. By providing an exposed treated surface, the active copper species is exposed to air or more readily leaches the surface of the article.
To improve processability, mechanical properties and interactions between the polymer and the glass described herein (including any fillers and/or additives that may be used), processing agents/aids may be included in the articles described herein. Exemplary processing agents/aids can include solid or liquid materials. The processing agents/aids may provide various extrusion benefits, and may include silicone based oil, wax and free flowing fluoropolymer. In other embodiments, the processing agents/aids may include compatibilizers/coupling agents, e.g., organosilicon compounds such as organo-silanes/siloxanes that are typically used in processing of polymer composites for improving mechanical and them1al properties. Such compatibilizers/coupling agents can be used to surface modify the glass and can include (3-acryloxy-propyl)trimethoxysilane; N-(2-aminoethyl)-3-aminopropyltrimethoxysilane; 3-aminopropyltri-ethoxysilane; 3-aminopropyltrimethoxysilane; (3-glycidoxypropyl)trimethoxysilane; 3-mercapto-propyltrimethoxysilane; 3-methacryloxypropyltrimethoxysilane; and vinyltrimethoxysilane.
In some embodiments, the articles described herein may include fillers including pigments, that are typically metal based inorganics can also be added for color and other purposes, e.g., aluminum pigments, copper pigments, cobalt pigments, manganese pigments, iron pigments, titanium pigments, tin pigments, clay earth pigments (naturally formed iron oxides), carbon pigments, antimony pigments, barium pigments, and zinc pigments.
After combining the antimicrobial glass described herein with a carrier, as described herein, the combination may be formed into a desired article. Examples of such articles include housings for electronic devices (e.g., mobile phones, smart phones, tablets, video players, information terminal devices, laptop computer, etc.), architectural structures (e.g., countertops or walls), appliances (e.g., cooktops, refrigerator and dishwasher doors, etc.), information displays (e.g., whiteboards), and automotive components (e.g., dashboard panels, windshields, window components, etc.).
In one or more embodiments, the articles may exhibit desired porosity and may be made into different shapes, including complex shapes and in different forms including plastics, rubbers and fiber/fabrics, which can have the same or different applications. Porous articles can also be used as antimicrobial filters. For example, the articles may be extruded into a honeycomb structure, which not only includes channels but also porous channel walls.
In other embodiments, the articles may include a high glass loading. Such articles may be formed from a melting process or the wet process. In such embodiments, in addition to using the articles themselves as an antimicrobial material, the polymer can be burnt out or removed to provide a pure copper glass antimicrobial article that is porous, with a simple or complex shape.
Cu(I) is an excellent catalyst for organic reactions, particularly for mild organic reactions, such as polymerization of acrylic monomers and oleochemical applications (e.g., hydrogenolysis of fatty esters to fatty alcohols including both methyl ester and wax ester processes, alkylation of alcohols with amines and amination of fatty alcohols), just to name a few. The articles described herein may be used for such applications.
Examples of the various uses and application of the articles described herein are shown in
The articles described herein, including the antimicrobial glass and a polymer, may exhibit a 2 log reduction or greater in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under the EPA Test. In some instances, the article exhibits at least a 4 log reduction, a 5 log reduction or even a 6 log reduction in the concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli under the EPA Test.
The articles described herein according to one or more embodiments may exhibit a 2 log reduction or greater (e.g., 3 log reduction or greater, 4 log reduction or greater, or 5 log reduction or greater) in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under the JIS Z 2801 (2000) testing conditions and/or the Modified JIS Z 2801 Test for Bacteria. One or more embodiments of the articles described herein also exhibit a 4 log reduction or greater (e.g., 5 log reduction or greater) in a concentration of Murine Norovirus (strain MNV-1), under the Modified JIS Z 2801 Test for Viruses.
The articles of one or more embodiments may exhibit the log reduction described herein for long periods of time. In other words, the article may exhibit extended or prolonged antimicrobial efficacy. For example, in some embodiments, the article may exhibit the log reductions in bacteria and/or viruses described herein for up to 1 month, up to 3 months, up to 6 months or up to 12 months after the antimicrobial glass is formed or after the antimicrobial glass is combined with a carrier. These time periods may start at or after the antimicrobial glass is formed or combined with a carrier.
In one or more embodiments, the article may include a coating that may be applied on a surface, forming a coated surface. The coated surface may exhibit a stable color that does not undergo substantial changes after exposure to specific environments. For example, the coated surface may exhibit a delta (Δ) E of less than about 2 or even less than about 1, as measured by ASTM D2247, after being exposed to a temperature of 38° C. at 100% relative humidity for 7 days. As used herein, the phrase “delta (Δ) E” refers to the total color distance as measured by the distance between two color coordinates, provided under the CIELAB color space (ΔE*ab=√{square root over ((L*2−L*1)2+(a*2−a*1)2+(b*2−b*1)2)}).
The coated surface may also exhibit chemical resistance to various chemicals, as measured by ASTM D1308, after exposure to chemicals in the center of a test piece for 1 hour.
The articles described herein may include pigments to impart color. Accordingly, the coatings made from such articles may exhibit a wide variety of colors, depending on the carrier color, mixture of carriers and amount of particle loading. Moreover, the articles and/or coatings described herein showed no adverse effect to paint adhesion as measured by ASTM D4541. In some instances, the adhesion of the article or coating to an underlying substrate was greater than the cohesive strength of the substrate. In other words, in testing, the adhesion between the coating and the substrate was so strong that the underlying substrate failed before the coating was separated from the surface of the substrate. For example, where the substrate includes wood, the adhesion between the coating and the substrate may be about 300 psi or greater, 400 psi or greater, 500 psi or greater, 600 psi or greater and all ranges-sub-ranges therebetween, as measured by ASTM D4541. In some instances, the article, when applied to a substrate as a coating, exhibits an anti-sag index value of about 3 or greater, about 5 or greater, 7 or greater, 8 or greater, 9 or greater, 10 or greater, 11 or greater, 12 or greater, 13 or greater, 14 or greater or even 15 or greater, as measured by ASTM D4400.
The article and/or coating may exhibit sufficient durability for use in household and commercial applications. Specifically, the article, when applied to a substrate as a coating, exhibits a scrub resistance as measured by ASTM D4213 of about 4 or greater, 5 or greater, 6 or greater, 7 or greater and all ranges and sub-ranges therebetween.
In one or more embodiments, the article and/or coating may be resistant to moisture. For example, after exposure of the article and/or coating to an environment of up to about 95% relative humidity for 24 hours, the article and/or coating exhibited no change in antimicrobial activity.
One or more embodiments of the article may include an antimicrobial glass and a carrier with a loading level of the antimicrobial glass such that the article exhibits resistance or preservation against the presence or growth of foulants. Foulants include fungi, bacteria, viruses and combinations thereof. In some instances, the presence or growth of foulants in articles, such as paints, varnishes and the like, can cause color changes to the article, can degrade the integrity of the article and negatively affect various properties of the article. By including a minimum loading of antimicrobial glass, (e.g., about 5 wt % or less, about 4 wt % or less, about 3 wt % or less, about 2 wt % or less, or about 1 wt % or less) to the carrier, the foulants can be eliminated or reduced. In some instances, the carrier formulation need not include certain components, when fouling is eliminated or reduced. Thus, the carrier formulations used in one or more embodiments of the articles described herein may have more flexibility and variations than previously possible, when in known articles that do not include the antimicrobial glass.
Another aspect of this disclosure pertains to a method of making an antimicrobial article. In one or more embodiments, the method includes melting a glass composition (such as the compositions disclosed herein) to form a glass, forming the glass into particles, fibers or a combination thereof, dispersing the particles and/or fibers into a carrier (e.g., polymer) to provide a filled polymer and forming the filled polymer into an antimicrobial article.
In one or more embodiments, method includes loading a selected amount of glass into the polymer, depending on the application of the article. Various methods and processes can be used to such as, for example, an in situ process through mixing monomers with the glass (which may be ground into particles or other form) and then polymerized (into a thermosetting or a thermoplastic polymer matrix) or by mixing polymer with the glass through a process of solution or melt compounding (e.g. using a Brabender compounder or an extruder, single screw or twin screw, reactive or non-reactive), etc.
In one or more embodiments, forming the filled polymer into the antimicrobial article may include extruding or molding the filled polymer. In one or more embodiments, the antimicrobial article may be further processed to expose at least a portion of the glass to an exterior surface. The exterior surface may be a surface with which the user of the antimicrobial article interacts (e.g., the exterior surface of a mobile phone, the display of the mobile phone etc.). In one or more embodiments, the method may include removing a surface portion of the antimicrobial article to expose the glass dispersed in the filled polymer. Exemplary methods of removing a surface portion of the antimicrobial article may include etching (by plasma, acid or mechanical means such as sanding or polishing).
Various embodiments will be further clarified by the following examples.
Non-limiting examples of compositions described herein are listed in Table 1. The compositions in Table 1 were batched, melted and formed into glasses. Table 2 lists selected properties of the compositions of Table 1 and/or glasses formed therefrom, including the conditions for melting, annealing, appearance of the melt, density, anneal point (as measured by Beam Bending Viscometer (BBV)), strain point (as measured by BBV), softening point (as measured by parallel plate viscometer (PPV)), Vickers hardness, Vickers crack initiation, fracture toughness by chevron notch, coefficient of thermal expansion, and other properties. Table 2 also includes the weight percent of Cu oxides, as determined by ICP techniques, and the ratio of Cu1+:Cu2+ for selected glasses.
Table 3 includes information related to the crystalline phases of crystal phase assemblages and/or crystal sizes of selected glasses as determined using X-ray diffraction (XRD) techniques known to those in the art, using such commercially available equipment as the model as a PW1830 (Cu Kα radiation) diffractometer manufactured by Philips, Netherlands. Spectra were typically acquired for 2θ from 5 to 80 degrees. Table 3 also includes elemental profile information of selected glasses determined by XPS techniques.
The glasses where then tested under the EPA test using Staphylococcus aureus under two conditions, as shown in Table 4. Table 4 also includes the total amount of Cu and Cu1+ found in selected examples, as determined by ICP techniques.
Regarding Example 13, SEM images indicate that phase separation occurred and included a glassy matrix phase and a dispersed glassy second phase. The dispersed phase is considered a degradable phase and included cuprite crystals. The degradation of the dispersed phase was evident when that phase partially dissolved when the formed glass was polished in water. EDS analysis showed a glassy phase enriched in silicon (i.e., a durable phase) relative to both the glassy second phase and crystalline phase. The crystalline phase was the most copper-rich. Without being bound by theory, it is believed that the glassy second phase is enriched in boron. The phase separation of the degradable phase (including the precipitation of cuprite crystals) occurred readily without additional heat treatment beyond simple post-melt annealing.
Phase separation of the glass upon melting is shown in
The release of the Cu1+ ions provides the antimicrobial activity, as demonstrated in the log reduction of Staphylococcus aureus under the EPA Test when the glass was tested as-received and after 1 day under the conditions listed in Table 4.
The antimicrobial performance of the glasses described herein was tested by forming a coupon or substrate article having dimensions of 2.5 cm×2.5 cm.
To test the antimicrobial activity of the examples, the EPA Test was utilized. In the examples described herein, Staphylococcus aureus (ATCC 6538) was cultured for 5 consecutive days before the testing was performed. Bacterial culture was mixed with serum (5% final concentration) and Triton X-100 (final concentration 0.01%). Each sample/carrier was inoculated with 20 ul of the bacterial suspension and allowed to dry (typically, for about 20 minutes to 40 minutes) at room temperature and 42% relative humidity prior to being exposed to bacterial for a 2 hour exposure period. After 2 hours of exposure, bacteria are washed from the carrier using neutralizer buffer and plated onto Tryptic soy agar plates. Twenty-four hours after incubation at 37° C., bacteria colony formation was examined and counted. Geometric mean and percent reduction were calculated based on the colony number from samples relative to glass carrier or appropriate paint control.
The articles according to one or more embodiments were formed as follows. The glass was ground into a powder and mixed with a commercially available carrier described as a clear gloss protective finish, available under the trademark Polycrylic® from Minwax Company. The copper loading (wt %/wt %) was either about 5%, 10% or 15% (calculated on the basis that the glass includes about 20 wt % Cu). The mixed carrier and glass powder was then brush coated onto Pyvek® paper that was backed with a polymer film, before being coated. The coated Pyvek® paper was cut into 2.5×2.5 cm coupons for the antimicrobial performance testing.
Where a thermoplastic polymer was utilized, the glass powder was compounded with a commercially available polymer, having the trademark Peralthane®, at a temperature in the range from between 195° C.-220° C. and a rate of 50 rpm. The loading of the glass was at about 60-80%. The resulting polymer and glass composite was made into 2.5×2.5 cm coupons by a hot press process.
In some examples, an epoxy resin was utilized. In such examples, about 3.0 g of a commercially available epoxy resin, Erisys GE22, was combined with about 1 g of a curing agent, Amicure PACM and 2 g of ethanol in a 20 mL vial, and mixed well. About 10 g of the powdered glass was added and mixed well. The resulting mixture was cured at room temperature for a few days and then the vial was broken to gel the combination, which was further dried at room temperature for one day and at 65° C. for several hours. This results in dried epoxy resin/glass composite.
The examples that were combined with an epoxy resin were also tested to determine the density or porosity of the composite. This included placing the example in water for 2 minutes and then removing the example. The mass difference before and after placement in the water was measured to demonstrate the porosity of the example.
Coupons made entirely of the glasses of Examples 4, 5, 6, 9, 10, 12, 13, 14 and 21 were tested under the EPA Test. In addition, a Comparative Substrate of pure copper metal was also tested under the EPA Test.
Glass 56 was formed into particles having an average major dimension of about 1 μm or less. The particles were combined with a polymer carrier. The loading of the particles in the carrier was about 5%. The antimicrobial efficacy, as measured by the EPA test for S. aureus was evaluated immediately after the combination of the particles and the polymer carrier, one week after combination of the particles and the polymer carrier, one month after combination of the particles and the polymer carrier and three months after combination of the particles and the polymer carrier.
Glass 56 and a Comparative Glass (A) (including 10% by weight silver ion content diffused therein) were evaluated for antimicrobial activity with respect to Murine Norovirus and cytotoxicity, under the Modified JIS Z 2801 Test for Viruses. Antimicrobial activity control samples and cytotoxicity control samples of Glass 56 and Comparative Glass A were also prepared, as described per the Modified JIS Z 2801 Test for Viruses. Table 5 shows the input virus control and the antimicrobial activity control results, Table 6 shows the cytotoxicity control results, Table 7 shows the results of Comparative Glass A after a 2-hour exposure time to Murine Norovirus, Table 8 shows the results of Glass 56 after a 2-hour exposure time to Murine Norovirus, Table 9 shows the cytotoxicity of Comparative Glass A and Glass 56 on RAW 264.7 cell cultures, and Table 10 shows the non-virucidal level of the test virus as measured on the cytotoxicity control samples for Comparative Glass A and Glass 56.
Murine Norovirus.
Murine Norovirus
Comparative Glass A exhibited a 0.33 log reduction in Murine Norovirus (or a 53.2% mean reduction), following a 2 hour exposure time at room temperature (20° C.) in a relative humidity of 42%, as compared to the antimicrobial activity control sample. Glass 56, however, exhibited a greater than 4.33 log reduction in Murine Norovirus (or 99.995% mean reduction or greater), following a 2 hour exposure time at room temperature (20° C.) in a relative humidity of 42%, as compared to the antimicrobial activity control sample.
Comparative Glass A did not demonstrate a mean reduction in viral titer of Murine Norovirus, following a 2 hour exposure time at room temperature (20° C.) in a relative humidity of 42%, in the presence of a 5% fetal bovine serum organic soil load, as compared to the cytotoxicity control sample. Glass 56, however, exhibited a greater than 3.67 mean log reduction Murine Norovirus (or at least 99.98% or greater mean reduction), following a 2 hour exposure time at room temperature (20° C.) in a relative humidity of 42%, in the presence of a 5% fetal bovine serum organic soil load, as compared to the cytotoxicity control sample.
The results shown in Table 10 indicate that each test sample was neutralized at a PFU50/250 μL of ≤1.5 log10.
Examples 12, 13 and 14 were formed into a powder and mixed with Polycrylic® at different loadings, based on Cu2O content. The mixtures were then coated onto Pyvek® paper (that was backed with a plastic film before coated) through a brushing process and cured for 1 week. The coated paper was cut into coupons for testing under the EPA Test.
Example 12 was ground into a powder and mixed with Pearlthane® polyurethane to provide a composite having different amounts of glass (by weight percent). The powdered glass and polyurethane were mixed at 195-220° C. for several minutes. The resulting combination was made into a 2.5 cm×2.5 cm coupon using melt processing, and evaluated for antimicrobial performance using the EPA Test. The results are provided in
Injection molded articles were formed to evaluate antimicrobial activity when the surface is typically covered by a thin layer of matrix polymer. In such articles, the matrix polymer is typically hydrophobic and may affect antimicrobial performance. As shown in
As discussed herein, thermoplastic polymers may be utilized to form the articles described herein through melt compounding processes. Articles using a thermoplastic polymer may also be formed by in situ polymerization and then into an article by a casting process. An epoxy resin (which is a thermosetting polymer) was used to demonstrate the concept. The epoxy resin was made from Erisys GE22 and Amicure PACM, which were mixed well in presence of alcohol. Example 12 was ground into a powder and added to the mixture according to Table 12, resulting in a paste-like material that was cast into a mold. In this example, a glass vial was used as a mold. The combination of the epoxy resin and ground glass was then cured at room temperature for a few days. The mold was then removed and the resulting article was dried at room temperature for one day and at 65° C. fora few hours.
Table 12: Composition for making an article with epoxy resin and ground glass from Example 12.
Depending on the loading of the glass in the article, the resulting article may be porous or dense. The porosity increases with the increase of glass loading as seen in Table 13, in which the water uptake by the articles was measured after soaking the article in water for 2 minutes. Different articles were made from the same epoxy as used in Table 12 was combined with different amounts of ground glass from Example 12. The article was made using gel casting.
It will be apparent to those skilled in the art that various modifications and variations can be made without departing from the spirit or scope of the invention.
This Application is a continuation of U.S. application Ser. No. 17/722,688 filed Apr. 18, 2022, which is a continuation of U.S. application Ser. No. 17/321,905 filed May 17, 2021, which issued Oct. 18, 2022 as U.S. Pat. No. 11,470,847 and which is a continuation of U.S. application Ser. No. 16/037,762 filed Jul. 17, 2018, which issued on Jun. 22, 2021 as U.S. Pat. No. 11,039,620 and is a continuation-in-part of U.S. application Ser. No. 15/446,223 filed Mar. 1, 2017, which issued on Jun. 22, 2021 as U.S. Pat. No. 11,039,619 and is a division of U.S. application Ser. No. 14/623,077 filed Feb. 16, 2015, which issued on Apr. 18, 2017 as U.S. Pat. No. 9,622,483 and claims priority to U.S. Application Nos. 62/034,842 filed Aug. 8, 2014, 62/034,834 filed Aug. 8, 2014, 62/026,186 filed Jul. 18, 2014, 62/026,177 filed Jul. 18, 2014, 61/992,987 filed May 14, 2014, 61/992,980 filed May 14, 2014, 61/941,690 filed Feb. 19, 2014, and 61/941,677 filed Feb. 19, 2014, each of which above applications is hereby incorporated by reference herein in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3414465 | Baak et al. | Dec 1968 | A |
| 3564587 | Leslie | Feb 1971 | A |
| 4053679 | Rinehart | Oct 1977 | A |
| 4098610 | Wexell | Jul 1978 | A |
| 4328022 | Bonk et al. | May 1982 | A |
| 5290544 | Shimono et al. | Mar 1994 | A |
| 5766611 | Shimono et al. | Jun 1998 | A |
| 6143318 | Gilchrist et al. | Nov 2000 | A |
| 6238686 | Burrell et al. | May 2001 | B1 |
| 6303183 | Wilczynski et al. | Oct 2001 | B1 |
| 6342460 | Akimoto et al. | Jan 2002 | B1 |
| 6417423 | Koper et al. | Jul 2002 | B1 |
| 6485735 | Steen et al. | Nov 2002 | B1 |
| 6485950 | Kumar et al. | Nov 2002 | B1 |
| 6582715 | Barry et al. | Jun 2003 | B1 |
| 6652875 | Bannister | Nov 2003 | B1 |
| 6749759 | Denes et al. | Jun 2004 | B2 |
| 6939820 | Numaguchi et al. | Sep 2005 | B2 |
| 7098256 | Ong et al. | Aug 2006 | B2 |
| 7192602 | Fechner et al. | Mar 2007 | B2 |
| 7282194 | Sung et al. | Oct 2007 | B2 |
| 7311944 | Sambasivan et al. | Dec 2007 | B2 |
| 7329301 | Chang et al. | Feb 2008 | B2 |
| 7357949 | Trogolo et al. | Apr 2008 | B2 |
| 7374693 | Routberg et al. | May 2008 | B1 |
| 7381751 | Sarangapani | Jun 2008 | B2 |
| 7390343 | Tepper et al. | Jun 2008 | B2 |
| 7491554 | Fujimura et al. | Feb 2009 | B2 |
| 7521056 | Chang et al. | Apr 2009 | B2 |
| 7521394 | Xie et al. | Apr 2009 | B2 |
| 7556789 | Fahlman | Jul 2009 | B2 |
| 7595355 | Trogolo | Sep 2009 | B2 |
| 7597900 | Zimmer et al. | Oct 2009 | B2 |
| 7704903 | Seneschal et al. | Apr 2010 | B2 |
| 7709027 | Fechner et al. | May 2010 | B2 |
| 7781498 | Krishnan | Aug 2010 | B2 |
| 7816292 | Zimmer et al. | Oct 2010 | B2 |
| 7833340 | Wakizaka et al. | Nov 2010 | B2 |
| 7963646 | Magdassi et al. | Jun 2011 | B2 |
| 8034732 | Kobayashi et al. | Oct 2011 | B2 |
| 8056733 | Koslow | Nov 2011 | B2 |
| 8080490 | Fechner et al. | Dec 2011 | B2 |
| 8083851 | Crudden et al. | Dec 2011 | B2 |
| 8092912 | Veerasamy et al. | Jan 2012 | B2 |
| 8187473 | Prasad | May 2012 | B2 |
| 8221833 | Veerasamy et al. | Jul 2012 | B2 |
| 8256233 | Boyden et al. | Sep 2012 | B2 |
| 8257714 | Aylsworth et al. | Sep 2012 | B2 |
| 8257732 | Huey et al. | Sep 2012 | B2 |
| 8258202 | Chasser et al. | Sep 2012 | B2 |
| 8258296 | Paredes et al. | Sep 2012 | B2 |
| 8262568 | Albrecht et al. | Sep 2012 | B2 |
| 8262868 | Brooks et al. | Sep 2012 | B2 |
| 8263114 | Berlat | Sep 2012 | B2 |
| 8263153 | Forchhammer et al. | Sep 2012 | B2 |
| 8263503 | Cawse et al. | Sep 2012 | B2 |
| 8263656 | Firooznia et al. | Sep 2012 | B2 |
| 8268343 | Saxena et al. | Sep 2012 | B2 |
| 8273303 | Ferlic et al. | Sep 2012 | B2 |
| 8273404 | Dave et al. | Sep 2012 | B2 |
| 8273452 | Guo et al. | Sep 2012 | B2 |
| 8277807 | Gallagher et al. | Oct 2012 | B2 |
| 8277827 | Toreki et al. | Oct 2012 | B2 |
| 8277899 | Krogman et al. | Oct 2012 | B2 |
| 8282776 | Smith et al. | Oct 2012 | B2 |
| 8317516 | Rusin et al. | Nov 2012 | B2 |
| 8568849 | Shi et al. | Oct 2013 | B2 |
| 8809820 | Dahm | Aug 2014 | B2 |
| 8900624 | Karandikar et al. | Dec 2014 | B2 |
| 9028962 | Borrelli et al. | May 2015 | B2 |
| 9115470 | Musick et al. | Aug 2015 | B2 |
| 9144242 | Averett et al. | Sep 2015 | B2 |
| 9193820 | Karandikar et al. | Nov 2015 | B2 |
| 9228090 | Musick | Jan 2016 | B2 |
| 9307759 | Musick | Apr 2016 | B2 |
| 20020045010 | Rohrbaugh et al. | Apr 2002 | A1 |
| 20020128249 | Cook | Sep 2002 | A1 |
| 20030167878 | Al-Salim et al. | Sep 2003 | A1 |
| 20030213503 | Price et al. | Nov 2003 | A1 |
| 20040110841 | Kite et al. | Jun 2004 | A1 |
| 20040206267 | Sambasivan et al. | Oct 2004 | A1 |
| 20040234604 | Mecking et al. | Nov 2004 | A1 |
| 20040253435 | Nomura | Dec 2004 | A1 |
| 20050010161 | Sun et al. | Jan 2005 | A1 |
| 20050031703 | Beier et al. | Feb 2005 | A1 |
| 20050090428 | Compans et al. | Apr 2005 | A1 |
| 20050095303 | Krenitski et al. | May 2005 | A1 |
| 20050152955 | Akhave et al. | Jul 2005 | A1 |
| 20050175552 | Hoic et al. | Aug 2005 | A1 |
| 20050175649 | Disalvo et al. | Aug 2005 | A1 |
| 20050182152 | Nonninger et al. | Aug 2005 | A1 |
| 20050207993 | Bazemore et al. | Sep 2005 | A1 |
| 20050224417 | Wien et al. | Oct 2005 | A1 |
| 20050224419 | Wien et al. | Oct 2005 | A1 |
| 20050258288 | Dalziel et al. | Nov 2005 | A1 |
| 20060115536 | Yacaman et al. | Jun 2006 | A1 |
| 20060127310 | Russell-Jones et al. | Jun 2006 | A1 |
| 20060142413 | Zimmer et al. | Jun 2006 | A1 |
| 20060166806 | Fechner et al. | Jul 2006 | A1 |
| 20060172013 | Hirai | Aug 2006 | A1 |
| 20060188580 | Sacks | Aug 2006 | A1 |
| 20060193902 | Tardi et al. | Aug 2006 | A1 |
| 20060198903 | Storey et al. | Sep 2006 | A1 |
| 20060272542 | Horner et al. | Dec 2006 | A1 |
| 20060280785 | Easterly et al. | Dec 2006 | A1 |
| 20060281961 | Prasad | Dec 2006 | A1 |
| 20060286051 | Tanaka et al. | Dec 2006 | A1 |
| 20070062870 | Chen et al. | Mar 2007 | A1 |
| 20070081958 | Bechert et al. | Apr 2007 | A1 |
| 20070116734 | Akash | May 2007 | A1 |
| 20070122356 | Kessler et al. | May 2007 | A1 |
| 20070122359 | Wang et al. | May 2007 | A1 |
| 20070158611 | Oldenburg | Jul 2007 | A1 |
| 20070195259 | Olsson | Aug 2007 | A1 |
| 20070196605 | Ong | Aug 2007 | A1 |
| 20070199890 | Trogolo | Aug 2007 | A1 |
| 20070208102 | Reynaud et al. | Sep 2007 | A1 |
| 20070225409 | Matsumoto | Sep 2007 | A1 |
| 20070243237 | Khaled et al. | Oct 2007 | A1 |
| 20070243263 | Trogolo | Oct 2007 | A1 |
| 20070254163 | Veerasamy et al. | Nov 2007 | A1 |
| 20070292355 | Tamarkin et al. | Dec 2007 | A1 |
| 20080031938 | Easterly et al. | Feb 2008 | A1 |
| 20080032060 | Nesbitt | Feb 2008 | A1 |
| 20080047894 | Trogolo et al. | Feb 2008 | A1 |
| 20080051493 | Trogolo et al. | Feb 2008 | A1 |
| 20080053922 | Honsinger et al. | Mar 2008 | A1 |
| 20080066741 | Lemahieu et al. | Mar 2008 | A1 |
| 20080085326 | Ruan | Apr 2008 | A1 |
| 20080156232 | Crudden et al. | Jul 2008 | A1 |
| 20080171068 | Wyner et al. | Jul 2008 | A1 |
| 20080220037 | Denizot et al. | Sep 2008 | A1 |
| 20080269186 | Bignozzi et al. | Oct 2008 | A1 |
| 20080292671 | Ho et al. | Nov 2008 | A1 |
| 20080292675 | Edermatt et al. | Nov 2008 | A1 |
| 20080299160 | Agboh et al. | Dec 2008 | A1 |
| 20090001012 | Kepner et al. | Jan 2009 | A1 |
| 20090012223 | Okada et al. | Jan 2009 | A1 |
| 20090023867 | Nishijima et al. | Jan 2009 | A1 |
| 20090048368 | Bash et al. | Feb 2009 | A1 |
| 20090068241 | Britz et al. | Mar 2009 | A1 |
| 20090098366 | Smoukov et al. | Apr 2009 | A1 |
| 20090104369 | Rajala et al. | Apr 2009 | A1 |
| 20090130161 | Sarangapani | May 2009 | A1 |
| 20090131517 | Height et al. | May 2009 | A1 |
| 20090133583 | Lee et al. | May 2009 | A1 |
| 20090133810 | Penalva | May 2009 | A1 |
| 20090142584 | Bedel et al. | Jun 2009 | A1 |
| 20090147370 | Parkin et al. | Jun 2009 | A1 |
| 20090151571 | Lee et al. | Jun 2009 | A1 |
| 20090162695 | Hevesi et al. | Jun 2009 | A1 |
| 20090186013 | Stucky et al. | Jul 2009 | A1 |
| 20090186756 | Cheng et al. | Jul 2009 | A1 |
| 20090209629 | Mirkin et al. | Aug 2009 | A1 |
| 20090232867 | Domb et al. | Sep 2009 | A1 |
| 20090263496 | Kijlstra et al. | Oct 2009 | A1 |
| 20090314628 | Lee et al. | Dec 2009 | A1 |
| 20090317435 | Vandesteeg et al. | Dec 2009 | A1 |
| 20090324990 | Pilloy et al. | Dec 2009 | A1 |
| 20100003203 | Karpov et al. | Jan 2010 | A1 |
| 20100004350 | Zalich et al. | Jan 2010 | A1 |
| 20100021559 | Kuznicki | Jan 2010 | A1 |
| 20100034873 | Delprete | Feb 2010 | A1 |
| 20100035047 | Ajayan et al. | Feb 2010 | A1 |
| 20100040655 | Ren et al. | Feb 2010 | A1 |
| 20100086605 | Bignozzi et al. | Apr 2010 | A1 |
| 20100098777 | Gould et al. | Apr 2010 | A1 |
| 20100111844 | Boyden et al. | May 2010 | A1 |
| 20100111845 | Boyden et al. | May 2010 | A1 |
| 20100119829 | Karpov et al. | May 2010 | A1 |
| 20100120942 | Ajayan et al. | May 2010 | A1 |
| 20100158851 | Yeung et al. | Jun 2010 | A1 |
| 20100178270 | Helling | Jul 2010 | A1 |
| 20100189901 | Chung et al. | Jul 2010 | A1 |
| 20100190004 | Gibbins et al. | Jul 2010 | A1 |
| 20100193744 | Avakian | Aug 2010 | A1 |
| 20100205709 | Grune et al. | Aug 2010 | A1 |
| 20100227052 | Carter et al. | Sep 2010 | A1 |
| 20100230344 | Srinivas et al. | Sep 2010 | A1 |
| 20100233146 | McDaniel | Sep 2010 | A1 |
| 20100234209 | Furukawa et al. | Sep 2010 | A1 |
| 20100247590 | Anton et al. | Sep 2010 | A1 |
| 20100255080 | Sanmiguel et al. | Oct 2010 | A1 |
| 20100264401 | Adivarahan et al. | Oct 2010 | A1 |
| 20100266646 | Dvorak et al. | Oct 2010 | A1 |
| 20100278771 | Lobe et al. | Nov 2010 | A1 |
| 20100297376 | Shi et al. | Nov 2010 | A1 |
| 20100304182 | Facchini et al. | Dec 2010 | A1 |
| 20100330380 | Colreavy et al. | Dec 2010 | A1 |
| 20110005997 | Kurth et al. | Jan 2011 | A1 |
| 20110014258 | Gan et al. | Jan 2011 | A1 |
| 20110014300 | Muthusamy et al. | Jan 2011 | A1 |
| 20110027385 | Cairns et al. | Feb 2011 | A1 |
| 20110027599 | Hoek et al. | Feb 2011 | A1 |
| 20110028311 | Etacheri et al. | Feb 2011 | A1 |
| 20110111204 | Veerasamy et al. | May 2011 | A1 |
| 20110127464 | Zinn et al. | Jun 2011 | A1 |
| 20110132144 | Mezger et al. | Jun 2011 | A1 |
| 20110143417 | Chang et al. | Jun 2011 | A1 |
| 20110144765 | Jones et al. | Jun 2011 | A1 |
| 20110155968 | Iha et al. | Jun 2011 | A1 |
| 20110182951 | Burger et al. | Jul 2011 | A1 |
| 20110189250 | John et al. | Aug 2011 | A1 |
| 20110193007 | Avakian | Aug 2011 | A1 |
| 20110193034 | Nakamoto et al. | Aug 2011 | A1 |
| 20110200656 | Olsson | Aug 2011 | A1 |
| 20110212832 | Nakano et al. | Sep 2011 | A1 |
| 20110217544 | Young et al. | Sep 2011 | A1 |
| 20110223057 | Della et al. | Sep 2011 | A1 |
| 20110223258 | Nikolaev | Sep 2011 | A1 |
| 20110226786 | Remington et al. | Sep 2011 | A1 |
| 20110236343 | Chisholm et al. | Sep 2011 | A1 |
| 20110236430 | Lin et al. | Sep 2011 | A1 |
| 20110236441 | Ohrlander et al. | Sep 2011 | A1 |
| 20110252580 | Miller et al. | Oct 2011 | A1 |
| 20110268802 | Dihora et al. | Nov 2011 | A1 |
| 20110281070 | Mittal et al. | Nov 2011 | A1 |
| 20110295190 | David et al. | Dec 2011 | A1 |
| 20110311604 | Xu et al. | Dec 2011 | A1 |
| 20120053276 | Hodson | Mar 2012 | A1 |
| 20120066956 | Lyngstadaas et al. | Mar 2012 | A1 |
| 20120070729 | Wertz et al. | Mar 2012 | A1 |
| 20120115981 | Verne et al. | May 2012 | A1 |
| 20120135226 | Bookbinder et al. | May 2012 | A1 |
| 20120145651 | Chen et al. | Jun 2012 | A1 |
| 20120223022 | Hassler et al. | Sep 2012 | A1 |
| 20120225027 | Exner et al. | Sep 2012 | A1 |
| 20120225905 | Padilla et al. | Sep 2012 | A1 |
| 20120230870 | Franciskovich et al. | Sep 2012 | A1 |
| 20120231704 | Mase | Sep 2012 | A1 |
| 20120232225 | Baker et al. | Sep 2012 | A1 |
| 20120232298 | Fang et al. | Sep 2012 | A1 |
| 20120234176 | Lee | Sep 2012 | A1 |
| 20120237406 | Lee | Sep 2012 | A1 |
| 20120237789 | Wang et al. | Sep 2012 | A1 |
| 20120240452 | Erdoes et al. | Sep 2012 | A1 |
| 20120241498 | Gonzalez et al. | Sep 2012 | A1 |
| 20120241502 | Aldridge et al. | Sep 2012 | A1 |
| 20120244139 | Madison et al. | Sep 2012 | A1 |
| 20120244369 | Ober et al. | Sep 2012 | A1 |
| 20120251381 | Bedworth et al. | Oct 2012 | A1 |
| 20120251517 | Frost et al. | Oct 2012 | A1 |
| 20120251756 | Buckley | Oct 2012 | A1 |
| 20120252774 | White et al. | Oct 2012 | A1 |
| 20120255623 | Bell et al. | Oct 2012 | A1 |
| 20120258176 | Sung et al. | Oct 2012 | A1 |
| 20120258244 | Veerasamy et al. | Oct 2012 | A1 |
| 20120258313 | Wen et al. | Oct 2012 | A1 |
| 20120259052 | Nelson et al. | Oct 2012 | A1 |
| 20120259073 | Ait-Haddou et al. | Oct 2012 | A1 |
| 20120259376 | Godden | Oct 2012 | A1 |
| 20120259391 | Godden | Oct 2012 | A1 |
| 20120261344 | Kurth et al. | Oct 2012 | A1 |
| 20120263807 | Horinek et al. | Oct 2012 | A1 |
| 20120263863 | Nesbitt | Oct 2012 | A1 |
| 20120264078 | Patel et al. | Oct 2012 | A1 |
| 20120264884 | Liu et al. | Oct 2012 | A1 |
| 20120269870 | Jiang et al. | Oct 2012 | A1 |
| 20120271248 | Nesbitt et al. | Oct 2012 | A1 |
| 20120271396 | Zheng et al. | Oct 2012 | A1 |
| 20120275960 | Seck | Nov 2012 | A1 |
| 20120276219 | Taylor et al. | Nov 2012 | A1 |
| 20120277085 | Bookbinder et al. | Nov 2012 | A1 |
| 20120279953 | Augustine et al. | Nov 2012 | A1 |
| 20120282434 | Cawse et al. | Nov 2012 | A1 |
| 20120283171 | Putman | Nov 2012 | A1 |
| 20120283172 | Wallen et al. | Nov 2012 | A1 |
| 20120283410 | Mirosevich et al. | Nov 2012 | A1 |
| 20120283538 | Rose et al. | Nov 2012 | A1 |
| 20120284946 | Green | Nov 2012 | A1 |
| 20120285574 | Mason | Nov 2012 | A1 |
| 20120288678 | Grube et al. | Nov 2012 | A1 |
| 20120288697 | Wu et al. | Nov 2012 | A1 |
| 20120288813 | Reid et al. | Nov 2012 | A1 |
| 20120289107 | Beissinger et al. | Nov 2012 | A1 |
| 20120289686 | Baker et al. | Nov 2012 | A1 |
| 20120289887 | Visco et al. | Nov 2012 | A1 |
| 20120296029 | Liu et al. | Nov 2012 | A1 |
| 20120296284 | Anderson et al. | Nov 2012 | A1 |
| 20120301533 | Uhlmann et al. | Nov 2012 | A1 |
| 20120304402 | Miracle et al. | Dec 2012 | A1 |
| 20120305132 | Maness | Dec 2012 | A1 |
| 20120305804 | Goldman | Dec 2012 | A1 |
| 20120308623 | Taxt-Lamolle et al. | Dec 2012 | A1 |
| 20120308630 | Averett et al. | Dec 2012 | A1 |
| 20120312797 | Augustine et al. | Dec 2012 | A1 |
| 20120315201 | Ferlic et al. | Dec 2012 | A1 |
| 20120315240 | Alper | Dec 2012 | A1 |
| 20120315336 | Ruddy et al. | Dec 2012 | A1 |
| 20120321553 | Zeng et al. | Dec 2012 | A1 |
| 20120321691 | Huey et al. | Dec 2012 | A1 |
| 20120321698 | Narain et al. | Dec 2012 | A1 |
| 20120321870 | Allen et al. | Dec 2012 | A1 |
| 20120322903 | Karandikar et al. | Dec 2012 | A1 |
| 20120328564 | Govindan et al. | Dec 2012 | A1 |
| 20120328615 | Romagne et al. | Dec 2012 | A1 |
| 20120328683 | Song et al. | Dec 2012 | A1 |
| 20120328713 | Olson et al. | Dec 2012 | A1 |
| 20120328804 | Allen et al. | Dec 2012 | A1 |
| 20120329675 | Olson et al. | Dec 2012 | A1 |
| 20130001066 | Brooks et al. | Jan 2013 | A1 |
| 20130001204 | Mistry et al. | Jan 2013 | A1 |
| 20130002776 | Nagashima et al. | Jan 2013 | A1 |
| 20130004778 | Tucker et al. | Jan 2013 | A1 |
| 20130005811 | Walcott et al. | Jan 2013 | A1 |
| 20130006184 | Albrecht et al. | Jan 2013 | A1 |
| 20130006194 | Anderson et al. | Jan 2013 | A1 |
| 20140017462 | Borrelli et al. | Jan 2014 | A1 |
| 20140120322 | Fu et al. | May 2014 | A1 |
| 20140170204 | Desai et al. | Jun 2014 | A1 |
| 20140194733 | Goforth et al. | Jul 2014 | A1 |
| 20140202943 | Pradeep et al. | Jul 2014 | A1 |
| 20140205546 | Macoviak | Jul 2014 | A1 |
| 20140220091 | Tofail et al. | Aug 2014 | A1 |
| 20140308867 | Van et al. | Oct 2014 | A1 |
| 20150208664 | Borrelli et al. | Jul 2015 | A1 |
| 20170283304 | Yamazaki et al. | Oct 2017 | A1 |
| 20180265398 | Yamazaki et al. | Sep 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 2503446 | May 2004 | CA |
| 2523365 | Oct 2004 | CA |
| 2515956 | Oct 2002 | CN |
| 1420146 | May 2003 | CN |
| 101189971 | Jun 2008 | CN |
| 101638537 | Feb 2010 | CN |
| 101805546 | Aug 2010 | CN |
| 101884807 | Nov 2010 | CN |
| 101889582 | Nov 2010 | CN |
| 102348844 | Feb 2012 | CN |
| 102380127 | Mar 2012 | CN |
| 0013906 | Aug 1980 | EP |
| 0665004 | Aug 1995 | EP |
| 0677989 | Sep 1998 | EP |
| 1748353 | Jan 2007 | EP |
| 1780318 | May 2007 | EP |
| 1809306 | Jul 2007 | EP |
| 1886981 | Feb 2008 | EP |
| 2004246 | Dec 2008 | EP |
| 2016115 | Jan 2009 | EP |
| 2016200 | Jan 2009 | EP |
| 2113282 | Nov 2009 | EP |
| 2123400 | Nov 2009 | EP |
| 2157211 | Feb 2010 | EP |
| 2303352 | Apr 2011 | EP |
| 2502941 | Sep 2012 | EP |
| 2506792 | Oct 2012 | EP |
| 2507248 | Oct 2012 | EP |
| 2508341 | Oct 2012 | EP |
| 2509622 | Oct 2012 | EP |
| 2509710 | Oct 2012 | EP |
| 2513238 | Oct 2012 | EP |
| 2514359 | Oct 2012 | EP |
| 2515855 | Oct 2012 | EP |
| 2516002 | Oct 2012 | EP |
| 2517720 | Oct 2012 | EP |
| 1715915 | Nov 2012 | EP |
| 2522377 | Nov 2012 | EP |
| 2537529 | Dec 2012 | EP |
| 1603600 | Jan 2013 | EP |
| 2540309 | Jan 2013 | EP |
| 2540491 | Jan 2013 | EP |
| 2540755 | Jan 2013 | EP |
| 2562624 | Feb 2013 | EP |
| 1263447 | Jun 2013 | EP |
| 2953213 | Jun 2011 | FR |
| 2473813 | Mar 2011 | GB |
| 2490239 | Oct 2012 | GB |
| 2490241 | Oct 2012 | GB |
| 2490242 | Oct 2012 | GB |
| 2490243 | Oct 2012 | GB |
| 2490644 | Nov 2012 | GB |
| 53-145824 | Dec 1978 | JP |
| 60-036349 | Feb 1985 | JP |
| 03-146436 | Jun 1991 | JP |
| 05-042624 | Jun 1993 | JP |
| 05-060670 | Sep 1993 | JP |
| 05-068530 | Sep 1993 | JP |
| 08-027404 | Jan 1996 | JP |
| 08-151229 | Jun 1996 | JP |
| 08-245237 | Sep 1996 | JP |
| 10-158033 | Jun 1998 | JP |
| 11-209143 | Aug 1999 | JP |
| 2000-191339 | Jul 2000 | JP |
| 2005-022916 | Jan 2005 | JP |
| 2008-500980 | Jan 2008 | JP |
| 4163778 | Oct 2008 | JP |
| 2011-105587 | Jun 2011 | JP |
| 5041636 | Oct 2012 | JP |
| 5042574 | Oct 2012 | JP |
| 5045015 | Oct 2012 | JP |
| 5046389 | Oct 2012 | JP |
| 5064311 | Oct 2012 | JP |
| 5074652 | Nov 2012 | JP |
| 5089165 | Dec 2012 | JP |
| 5099520 | Dec 2012 | JP |
| 2013-233492 | Nov 2013 | JP |
| 10-2007-0015393 | Feb 2007 | KR |
| 2011-0127748 | Nov 2011 | KR |
| 2414902 | Mar 2011 | RU |
| 201245089 | Nov 2012 | TW |
| 0027768 | May 2000 | WO |
| 0047528 | Aug 2000 | WO |
| 0318494 | Mar 2003 | WO |
| 0350052 | Jun 2003 | WO |
| 2005079738 | Sep 2005 | WO |
| 2006048879 | May 2006 | WO |
| 2007071991 | Jun 2007 | WO |
| 2007076413 | Jul 2007 | WO |
| 2007101062 | Sep 2007 | WO |
| 2007120616 | Oct 2007 | WO |
| 2007127211 | Nov 2007 | WO |
| 2007131145 | Nov 2007 | WO |
| 2007134176 | Nov 2007 | WO |
| 2009100164 | Aug 2009 | WO |
| 2009154903 | Dec 2009 | WO |
| 2010041760 | Apr 2010 | WO |
| 2010068985 | Jun 2010 | WO |
| 2011047312 | Apr 2011 | WO |
| 2011053562 | May 2011 | WO |
| 2011053719 | May 2011 | WO |
| 2011056934 | May 2011 | WO |
| 2011057111 | May 2011 | WO |
| 2011062938 | May 2011 | WO |
| 2011063259 | May 2011 | WO |
| 2011063990 | Jun 2011 | WO |
| 2011065997 | Jun 2011 | WO |
| 2011068250 | Jun 2011 | WO |
| 2011068545 | Jun 2011 | WO |
| 2011068892 | Jun 2011 | WO |
| 2011069163 | Jun 2011 | WO |
| 2011070364 | Jun 2011 | WO |
| 2011071130 | Jun 2011 | WO |
| 2011071904 | Jun 2011 | WO |
| 2011072045 | Jun 2011 | WO |
| 2011072392 | Jun 2011 | WO |
| 2011073969 | Jun 2011 | WO |
| 2011075798 | Jun 2011 | WO |
| 2011075804 | Jun 2011 | WO |
| 2011076843 | Jun 2011 | WO |
| 2011078804 | Jun 2011 | WO |
| 2011079075 | Jun 2011 | WO |
| 2011084464 | Jul 2011 | WO |
| 2011084811 | Jul 2011 | WO |
| 2011090760 | Jul 2011 | WO |
| 2011092522 | Aug 2011 | WO |
| 2011094293 | Aug 2011 | WO |
| 2011097347 | Aug 2011 | WO |
| 2011100425 | Aug 2011 | WO |
| 2011101642 | Aug 2011 | WO |
| 2011103183 | Aug 2011 | WO |
| 2011103578 | Aug 2011 | WO |
| 2011107592 | Sep 2011 | WO |
| 2011109136 | Sep 2011 | WO |
| 2011109400 | Sep 2011 | WO |
| 2011145592 | Nov 2011 | WO |
| 2012015362 | Feb 2012 | WO |
| 2012066172 | May 2012 | WO |
| 2012129305 | Sep 2012 | WO |
| 2012135193 | Oct 2012 | WO |
| 2012135194 | Oct 2012 | WO |
| 2012135294 | Oct 2012 | WO |
| 2012159632 | Nov 2012 | WO |
| 2013027675 | Feb 2013 | WO |
| 2014025949 | Feb 2014 | WO |
| 2014085349 | Jun 2014 | WO |
| 2014085379 | Jun 2014 | WO |
| 2014085863 | Jun 2014 | WO |
| 2016104454 | Jun 2016 | WO |
| Entry |
|---|
| Ahmed et al., “Effect of Heat Treatment on the Crystallisation of Cuprous Oxide in Glass,” Glass Research Laboratory, National Research Center, Dokki, Cairo, Egypt, Glass Technology, vol. 22, No. 1, Feb. 1981. |
| Atsuo Yasumori, “Phase Separation and High-Performance realization of Sodium Borosilicate Glasses”, New Glass, vol. 28, No. 108, 2013, 16 pages (8 pages of English Translation and 8 pages of Original Document). |
| Bolshii, Y. et al., “Formation and Some Physicochemical Properties of Glasses of The CuO—SiO2—P2O5 System.” Izvestiya Akademii Nauk Latviiskoi SSR, No. 2, pp. 194, 1983. |
| English Translation of CN201580020546.6 Second Office Action Mailed Apr. 30, 2019, China Patent Office, 18 pgs. |
| English Translation of JP2016552903 Office Action Dated Jun. 19, 2019; 4 Pages; Japan Patent Office. |
| English Translation of JP2016552903 Office Action Issued Oct. 24, 2018; 4 Pages; Japanese Patent Office. |
| Esteban-Tejeda et al. “Antibacterial and Antifungal Activity of a Soda-Lime Glass Containing Copper Nanoparticles,” Nanotechnology 20 (2009) 505701 (6pp). |
| Esteban-Tejeda et al., “Glass-(nAg, nCu) Biocide Coatings on Ceramic Oxide Substrates.” Plos One, Mar. 2012, vol. 7, Issue 3, p. 1-6. |
| European Patent Application No. 15708068.0 Communication pursuant to Article 94(3) EPC dated Apr. 26, 2023; 6 Pages; European Patent Office. |
| Hamzawy et al. “Crystallisation of Cu-containing K-fluor-richterite (KNaCa(Mg, Cu)5 Si8O22F2) glasses.” Glass Technology, 2005, 46 (3), 281-286. |
| Japanese Patent Application No. 2016-552903, Decision to Grant dated Apr. 7, 2021, 6 pages (2 pages of English Translation and 4 pages of Original Document); Japanese Patent Office. |
| Japanese Patent Office, Decision of Rejection for Japanese Patent Application No. 2016-552903, Oct. 7, 2020, 8 pages. |
| Johan et al., “Annealing Effects on the Properties of Copper Oxide Thin Films Prepared by Chemical Deposition”, International Journal of Electrochemical Science, vol. 6, 2011, pp. 6094-6104. |
| Korean Patent Application No. 10-2021-7033046, Office Action, dated Jun. 8, 2022, 8 pages (5 pages of English Translation and 3 pages of Original Document), Korean Patent Office. |
| Korean Patent Application No. 2016-7025733, office action dated Feb. 26, 2021, 5 pages (5 pages of English Translation); Korean Patent Office. |
| Lozano et al. WO 2012/066172; published: May 24, 2012; English Machine translation obtained on Apr. 24, 2020. (Year: 2012). |
| Matusita, K., et al., “Thermal Expansion of Substituted Copper Aluminosilicate Glasses.” Journal of American Ceramic Society, vol. 66, No. 1, pp. 33-35, 1982. |
| Murata et al. WO 2013/027675, English machine translation obtained on Oct. 12, 2022. (Year: 2022). |
| Patent Cooperation Treaty International Notification of Transmittal of the International Search Report and The Written Opinion of the International Searching Authority, international application No. PCT/US2015/016104: mailing date Jun. 25, 2015, 15 pages. |
| Paul, “Chemistry of glasses”, Wuhan University of Technology Press, Mar. 1992, pp. 316-320 (translation attached). |
| Sakaino, T. et al., “A Study on the Coloring Process of Copper Ruby Glass.” The Journal of the Ceramic Association of Japan, vol. 69, ISSUE 792, pp. 434-438, Jan. 1961. |
| Sherwin Williams Copper Bottom Anti-Fouling Paint #45, downloaded May 7, 2015. |
| Taiwan Patent Office; Official Letter for Taiwan Invention Patent Application No. 104105874; Jun. 21, 2018; 7 pages. |
| Taiwan Patent Office; Search Report for Taiwan Invention Patent Application No. 104105874; Jun. 14, 2018; 1 page. |
| Tret'yakova N. et al., “The Effect of Divalent Metal Oxides on the Viscosity of Simple Silicate Glasses.” Deposited in VINITI, No. DEP1091-69, pp. 1-19, 1969. |
| Number | Date | Country | |
|---|---|---|---|
| 20240008493 A1 | Jan 2024 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62034842 | Aug 2014 | US | |
| 62034834 | Aug 2014 | US | |
| 62026186 | Jul 2014 | US | |
| 62026177 | Jul 2014 | US | |
| 61992987 | May 2014 | US | |
| 61992980 | May 2014 | US | |
| 61941690 | Feb 2014 | US | |
| 61941677 | Feb 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14623077 | Feb 2015 | US |
| Child | 15446223 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17722688 | Apr 2022 | US |
| Child | 18229728 | US | |
| Parent | 17321905 | May 2021 | US |
| Child | 17722688 | US | |
| Parent | 16037762 | Jul 2018 | US |
| Child | 17321905 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15446223 | Mar 2017 | US |
| Child | 16037762 | US |
